Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Cadila

    Jump to

    • Zydus Lifesciences: Time to book profit?

      Transitional opportunity due to Revlimid helped this quarter, though remaining quarters may not witness a similar contribution. Hence, margins are likely to moderate.

    • Zydus Lifesciences: Why we still remain positive

      Annual sales traction from Revlimid is decent and it is likely to stay so till 2026. The management is also positive about the product pipeline

    • Zydus Lifesciences: Time to book profit, post strong rally over a year?

    • Zydus Lifesciences: Transdermal opportunity to unfold

    • Cadila in talks with Centre, states for supply of three-dose rabies vaccine

    • Zydus Lifesciences: Nephrology, biosimilar scope takes focus

    • Cadila Pharma launches drug to treat high LDL-cholesterol

    • Cadila: Biosimilars, oncology portfolio hold promise for medium term

    • Cadila: Unfolding vaccine opportunity can offset US headwinds

    • Cadila: More a COVID hedge in the near term

    • Herd Immunity Part 2: Is the race a sprint or a marathon?

    • Deregulation of vaccine rollout: What it means for pharma players

    • Weekly Tactical Pick | Cadila Healthcare

    • Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?

    • Cadila Q4 PAT seen up 13.7% YoY to Rs. 505 cr: Sharekhan

    • What ‘second wave’ means for investors in Indian pharma

    • Cadila: COVID vaccine to be the key differentiator in the near term

    • COVID Vaccine: The opportunities for investors - Part I

    • Cadila Q2: Strong operational show backed by traction in COVID portfolio

    • Zydus Cadila gets USFDA nod to market generic antihistamine tablets

    • US FDA tailwind: Structural or situational?

    • Pharma companies that can benefit from the demand for complex respiratory drugs

    • Cadila Q3 PAT may dip 29.7% YoY to Rs. 382 cr: Sharekhan

    • Cadila Q2 PAT may dip 23.3% YoY to Rs. 386 cr: Sharekhan

    • Buy Cadila; target of Rs 540: Axis Direct

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347